CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] LICENSE, SUPPLY AND...License, Supply and Commercialization Agreement • August 7th, 2024 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License, Supply and Commercialization Agreement, is made as of July 23, 2024 (the “Effective Date”), by and between Catalyst Pharmaceuticals Inc., having a place of business at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33155 USA (“Catalyst”), and KYE Pharmaceuticals Inc., having a place of business at 2233 Argentia Rd. Suites 302 & 302A, Mississauga ON, L5N 2X7 (“KYE”). Each of KYE and Catalyst may be referred to herein as a “Party” or collectively as the “Parties”.
TLC and Strides Enter Agreement for AmphoTLC™ in IndiaLicense Supply and Commercialization Agreement • May 27th, 2021
27, 2021 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Strides Pharma Science Limited (Strides, BSE: 532531, NSE: STAR), a global pharmaceutical company, have entered a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.
